Recap - This week was jam-packed with market-moving events in biotech, punctuated on Thursday afternoon with an accounting scandal of epic proportions at Salix Pharmaceuticals (SLXP), which makes up … Continue Reading
Read NowRecap - Despite this asset class having just entered human testing, there’s significant excitement surrounding the therapeutic potential of blocking CD47 and the “DO NOT EAT” signal … Continue Reading
Read NowRecap - What a week. The iShares NASDAQ Biotechnology (IBB) made new all-time highs and is drastically outpacing the S&P 500, as well as the NASDAQ composite, for the … Continue Reading
Read NowInsights - In last week’s biotech recap, and again at PropThink.com this week, we outlined some key support levels for the S&P 500 (SPX or SPY), explaining … Continue Reading
Read NowRecap - Johnson & Johnson (JNJ) is shelling out $1.75 billion to acquire Alios Biopharma, a private developer of therapeutics for viral diseases. Alios’ lead drug asset … Continue Reading
Read NowInsights - Esperion Therapeutics Inc (ESPR) hit a home run with top-line results from ETC-1002-008, a 12-week Phase 2b study that is one of the largest ever … Continue Reading
Read Now
